Aberrant DNA methylation characterizes juvenile myelomonocytic leukemia with poor outcome

Christiane Olk-Batz, Anna R. Poetsch, Peter Nöllke, Rainer Claus, Manuela Zucknick, Inga Sandrock, Tania Witte, Brigitte Strahm, Henrik Hasle, Marco Zecca, Jan Starý, Eva Bergstraesser, Barbara De Moerloose, Monika Trebo, Marry M. Van Den Heuvel-Eibrink, Dorota Wojcik, Franco Locatelli, Christoph Plass, Charlotte M. Niemeyer, Christian Flotho

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Aberrant DNA methylation contributes to the malignant phenotype in virtually all types of cancer, including myeloid leukemia. We hypothesized that CpG island hypermethylation also occurs in juvenile myelomonocytic leukemia (JMML) and investigated whether it is associated with clinical, hematologic, or prognostic features. Based on quantitative measurements of DNA methylation in 127 JMML cases using mass spectrometry (MassARRAY), we identified 4 gene CpG islands with frequent hypermethylation: BMP4 (36% of patients), CALCA (54%), CDKN2B (22%), and RARB (13%). Hypermethylation was significantly associated with poor prognosis: when the methylation data were transformed into prognostic scores using a LASSO Cox regression model, the 5-year overall survival was 0.41 for patients in the top tertile of scores versus 0.72 in the lowest score tertile (P = .002). Among patients given allogeneic hematopoietic stem cell transplantation, the 5-year cumulative incidence of relapse was 0.52 in the highest versus 0.10 in the lowest score tertile (P = .007). In multivariate models, DNA methylation retained prognostic value independently of other clinical risk factors. Longitudinal analyses indicated that some cases acquired a more extensively methylated phenotype at relapse. In conclusion, our data suggest that a high-methylation phenotype characterizes an aggressive biologic variant of JMML and is an important molecular predictor of outcome.

Original languageEnglish
Pages (from-to)4871-4880
Number of pages10
JournalBlood
Volume117
Issue number18
DOIs
Publication statusPublished - May 5 2011

Fingerprint

Juvenile Myelomonocytic Leukemia
DNA Methylation
CpG Islands
Methylation
Phenotype
Recurrence
Myeloid Leukemia
Hematopoietic Stem Cell Transplantation
Stem cells
Proportional Hazards Models
Mass spectrometry
Mass Spectrometry
Genes
Survival
Incidence
Neoplasms

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Olk-Batz, C., Poetsch, A. R., Nöllke, P., Claus, R., Zucknick, M., Sandrock, I., ... Flotho, C. (2011). Aberrant DNA methylation characterizes juvenile myelomonocytic leukemia with poor outcome. Blood, 117(18), 4871-4880. https://doi.org/10.1182/blood-2010-08-298968

Aberrant DNA methylation characterizes juvenile myelomonocytic leukemia with poor outcome. / Olk-Batz, Christiane; Poetsch, Anna R.; Nöllke, Peter; Claus, Rainer; Zucknick, Manuela; Sandrock, Inga; Witte, Tania; Strahm, Brigitte; Hasle, Henrik; Zecca, Marco; Starý, Jan; Bergstraesser, Eva; De Moerloose, Barbara; Trebo, Monika; Van Den Heuvel-Eibrink, Marry M.; Wojcik, Dorota; Locatelli, Franco; Plass, Christoph; Niemeyer, Charlotte M.; Flotho, Christian.

In: Blood, Vol. 117, No. 18, 05.05.2011, p. 4871-4880.

Research output: Contribution to journalArticle

Olk-Batz, C, Poetsch, AR, Nöllke, P, Claus, R, Zucknick, M, Sandrock, I, Witte, T, Strahm, B, Hasle, H, Zecca, M, Starý, J, Bergstraesser, E, De Moerloose, B, Trebo, M, Van Den Heuvel-Eibrink, MM, Wojcik, D, Locatelli, F, Plass, C, Niemeyer, CM & Flotho, C 2011, 'Aberrant DNA methylation characterizes juvenile myelomonocytic leukemia with poor outcome', Blood, vol. 117, no. 18, pp. 4871-4880. https://doi.org/10.1182/blood-2010-08-298968
Olk-Batz C, Poetsch AR, Nöllke P, Claus R, Zucknick M, Sandrock I et al. Aberrant DNA methylation characterizes juvenile myelomonocytic leukemia with poor outcome. Blood. 2011 May 5;117(18):4871-4880. https://doi.org/10.1182/blood-2010-08-298968
Olk-Batz, Christiane ; Poetsch, Anna R. ; Nöllke, Peter ; Claus, Rainer ; Zucknick, Manuela ; Sandrock, Inga ; Witte, Tania ; Strahm, Brigitte ; Hasle, Henrik ; Zecca, Marco ; Starý, Jan ; Bergstraesser, Eva ; De Moerloose, Barbara ; Trebo, Monika ; Van Den Heuvel-Eibrink, Marry M. ; Wojcik, Dorota ; Locatelli, Franco ; Plass, Christoph ; Niemeyer, Charlotte M. ; Flotho, Christian. / Aberrant DNA methylation characterizes juvenile myelomonocytic leukemia with poor outcome. In: Blood. 2011 ; Vol. 117, No. 18. pp. 4871-4880.
@article{4b7f9c7b5233406ea4de44d4cceb487f,
title = "Aberrant DNA methylation characterizes juvenile myelomonocytic leukemia with poor outcome",
abstract = "Aberrant DNA methylation contributes to the malignant phenotype in virtually all types of cancer, including myeloid leukemia. We hypothesized that CpG island hypermethylation also occurs in juvenile myelomonocytic leukemia (JMML) and investigated whether it is associated with clinical, hematologic, or prognostic features. Based on quantitative measurements of DNA methylation in 127 JMML cases using mass spectrometry (MassARRAY), we identified 4 gene CpG islands with frequent hypermethylation: BMP4 (36{\%} of patients), CALCA (54{\%}), CDKN2B (22{\%}), and RARB (13{\%}). Hypermethylation was significantly associated with poor prognosis: when the methylation data were transformed into prognostic scores using a LASSO Cox regression model, the 5-year overall survival was 0.41 for patients in the top tertile of scores versus 0.72 in the lowest score tertile (P = .002). Among patients given allogeneic hematopoietic stem cell transplantation, the 5-year cumulative incidence of relapse was 0.52 in the highest versus 0.10 in the lowest score tertile (P = .007). In multivariate models, DNA methylation retained prognostic value independently of other clinical risk factors. Longitudinal analyses indicated that some cases acquired a more extensively methylated phenotype at relapse. In conclusion, our data suggest that a high-methylation phenotype characterizes an aggressive biologic variant of JMML and is an important molecular predictor of outcome.",
author = "Christiane Olk-Batz and Poetsch, {Anna R.} and Peter N{\"o}llke and Rainer Claus and Manuela Zucknick and Inga Sandrock and Tania Witte and Brigitte Strahm and Henrik Hasle and Marco Zecca and Jan Star{\'y} and Eva Bergstraesser and {De Moerloose}, Barbara and Monika Trebo and {Van Den Heuvel-Eibrink}, {Marry M.} and Dorota Wojcik and Franco Locatelli and Christoph Plass and Niemeyer, {Charlotte M.} and Christian Flotho",
year = "2011",
month = "5",
day = "5",
doi = "10.1182/blood-2010-08-298968",
language = "English",
volume = "117",
pages = "4871--4880",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "18",

}

TY - JOUR

T1 - Aberrant DNA methylation characterizes juvenile myelomonocytic leukemia with poor outcome

AU - Olk-Batz, Christiane

AU - Poetsch, Anna R.

AU - Nöllke, Peter

AU - Claus, Rainer

AU - Zucknick, Manuela

AU - Sandrock, Inga

AU - Witte, Tania

AU - Strahm, Brigitte

AU - Hasle, Henrik

AU - Zecca, Marco

AU - Starý, Jan

AU - Bergstraesser, Eva

AU - De Moerloose, Barbara

AU - Trebo, Monika

AU - Van Den Heuvel-Eibrink, Marry M.

AU - Wojcik, Dorota

AU - Locatelli, Franco

AU - Plass, Christoph

AU - Niemeyer, Charlotte M.

AU - Flotho, Christian

PY - 2011/5/5

Y1 - 2011/5/5

N2 - Aberrant DNA methylation contributes to the malignant phenotype in virtually all types of cancer, including myeloid leukemia. We hypothesized that CpG island hypermethylation also occurs in juvenile myelomonocytic leukemia (JMML) and investigated whether it is associated with clinical, hematologic, or prognostic features. Based on quantitative measurements of DNA methylation in 127 JMML cases using mass spectrometry (MassARRAY), we identified 4 gene CpG islands with frequent hypermethylation: BMP4 (36% of patients), CALCA (54%), CDKN2B (22%), and RARB (13%). Hypermethylation was significantly associated with poor prognosis: when the methylation data were transformed into prognostic scores using a LASSO Cox regression model, the 5-year overall survival was 0.41 for patients in the top tertile of scores versus 0.72 in the lowest score tertile (P = .002). Among patients given allogeneic hematopoietic stem cell transplantation, the 5-year cumulative incidence of relapse was 0.52 in the highest versus 0.10 in the lowest score tertile (P = .007). In multivariate models, DNA methylation retained prognostic value independently of other clinical risk factors. Longitudinal analyses indicated that some cases acquired a more extensively methylated phenotype at relapse. In conclusion, our data suggest that a high-methylation phenotype characterizes an aggressive biologic variant of JMML and is an important molecular predictor of outcome.

AB - Aberrant DNA methylation contributes to the malignant phenotype in virtually all types of cancer, including myeloid leukemia. We hypothesized that CpG island hypermethylation also occurs in juvenile myelomonocytic leukemia (JMML) and investigated whether it is associated with clinical, hematologic, or prognostic features. Based on quantitative measurements of DNA methylation in 127 JMML cases using mass spectrometry (MassARRAY), we identified 4 gene CpG islands with frequent hypermethylation: BMP4 (36% of patients), CALCA (54%), CDKN2B (22%), and RARB (13%). Hypermethylation was significantly associated with poor prognosis: when the methylation data were transformed into prognostic scores using a LASSO Cox regression model, the 5-year overall survival was 0.41 for patients in the top tertile of scores versus 0.72 in the lowest score tertile (P = .002). Among patients given allogeneic hematopoietic stem cell transplantation, the 5-year cumulative incidence of relapse was 0.52 in the highest versus 0.10 in the lowest score tertile (P = .007). In multivariate models, DNA methylation retained prognostic value independently of other clinical risk factors. Longitudinal analyses indicated that some cases acquired a more extensively methylated phenotype at relapse. In conclusion, our data suggest that a high-methylation phenotype characterizes an aggressive biologic variant of JMML and is an important molecular predictor of outcome.

UR - http://www.scopus.com/inward/record.url?scp=79955968990&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955968990&partnerID=8YFLogxK

U2 - 10.1182/blood-2010-08-298968

DO - 10.1182/blood-2010-08-298968

M3 - Article

C2 - 21406719

AN - SCOPUS:79955968990

VL - 117

SP - 4871

EP - 4880

JO - Blood

JF - Blood

SN - 0006-4971

IS - 18

ER -